Okabe Toshitaka, Yakushiji Tadayuki, Isomura Naoei, Ochiai Masahiko
Division of Cardiology, Showa University Northern Yokohama Hospital, 35-1, Chigasaki-Chuo, Tsuzuki, Yokohama 224-8503, Japan.
Eur Heart J Case Rep. 2021 Mar 10;5(3):ytab087. doi: 10.1093/ehjcr/ytab087. eCollection 2021 Mar.
Coronary artery disease is uncommon in patients with essential thrombocythaemia (ET); therefore, no treatment strategies have been established.
A 68-year-old man visited our hospital with worsening effort angina complicated with ET. Coronary angiography (CAG) revealed moderate stenosis of the left main trunk and left anterior descending artery (LAD). We planned to perform percutaneous coronary intervention (PCI) only after the patient's platelet count had fallen below 600 000/μL. Platelet factor 4 levels were markedly elevated (355.0 ng/mL; the normal range is <20 ng/mL). We observed a lesion in the proximal left circumflex artery and stenosis progression in the LAD at the time of the PCI, neither of which had been detected at the previous CAG. During the PCI procedure, argatroban was infused to maintain the activated clotting time (ACT) above 250 s. The PCI was performed successfully without any complications. Follow-up CAG showed no restenosis, and no bleeding complications were observed during the course.
In patients with ET, it may be useful to measure platelet factor 4 before PCI and to monitor ACT during the procedure. When heparin resistance is suspected based on blood coagulation tests, infusion of direct thrombin inhibitor during PCI may be considered, with anticoagulation monitoring by ACT.
冠状动脉疾病在原发性血小板增多症(ET)患者中并不常见;因此,尚未确立治疗策略。
一名68岁男性因劳力性心绞痛加重并合并ET前来我院就诊。冠状动脉造影(CAG)显示左主干和左前降支动脉(LAD)中度狭窄。我们计划仅在患者血小板计数降至600 000/μL以下后才进行经皮冠状动脉介入治疗(PCI)。血小板因子4水平显著升高(355.0 ng/mL;正常范围<20 ng/mL)。在PCI时,我们观察到左回旋支动脉近端有病变,LAD狭窄进展,而在之前的CAG中均未检测到。在PCI过程中,输注阿加曲班以维持活化凝血时间(ACT)在250秒以上。PCI成功进行,无任何并发症。随访CAG显示无再狭窄,病程中未观察到出血并发症。
对于ET患者,PCI前测量血小板因子4并在手术过程中监测ACT可能有用。当根据凝血试验怀疑肝素抵抗时,PCI期间可考虑输注直接凝血酶抑制剂,并通过ACT进行抗凝监测。